Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 3 , Pages 467-482 , September 2006

Hypertension in Cushing's syndrome

References 

  1. Kamilaris T, Chrousos GP. Adrenal diseases. In:  Moore WT,  Eastman R editor. Diagnostic Endocrinology. Toronto, CA: BC Decker; 1989;p. 79–109
  2. Magiakou MA, Mastorakos G, Oldfield EH, et al. Cushing's syndrome in children and adolescents; presentation, diagnosis and therapy. The New England Journal of Medicine. 1994;331:629–636
  3. Ross EJ, Linch DC. Cushing's syndrome – killing disease. Discriminatory value of signs and symptoms aiding early diagnosis. Lancet. 1982;2:646–649
  4. Stewart PM, Walker BR, Holder G. 11 beta-hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. The Journal of Clinical Endocrinology and Metabolism. 1995;80:3617–3620
  5. Magiakou MA, Mastorakos G, Zachman K, et al. Blood pressure in children and adolescents with Cushing's syndrome before and after surgical cure. The Journal of Clinical Endocrinology and Metabolism. 1997;82:1734–1738
  6. Ross EJ, Marshall-Jones P, Friedman M. Cushing syndrome: diagnostic criteria. The Quarterly Journal of Medicine. 1966;35:149–192
  7. Imai Y, Abe K, Sasaki S, et al. Altered circadian blood pressure rhythm in patients with Cushing's syndrome. Hypertension. 1988;12:11–19
  8. Fraser R, Davies DL, Connell JM. Hormones and hypertension. Clinical Endocrinology. 1989;31:701–746
  9. Williamson PM, Kelly JJ, Whitworth JA. Dose response relationships and mineralocorticoid activity in cortisol induced hypertension in humans. Journal of Hypertension. 1996;14(supplement):S37–S41
  10. de Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacological Reviews. 2000;52:415–472
  11. Dinh DT, Frauman AG, Johnston CI, et al. Angiotensin receptors: distribution, signalling and function. Clinical Science (London). 2001;100:481–492
  12. Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Medical Science Monitor. 2005;11(6):RA194–RA205
  13. Suzuki Y, Ruiz-Ortega M, Lorenzo O, et al. Inflammation and angiotensin II. The International Journal of Biochemistry & Cell Biology. 2003;35:881–900
  14. Bader M, Peters J, Baltatu O, et al. Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. Journal of Molecular Medicine. 2001;79:76–102
  15. Alvarez A, Cerda-Nicolas M, Naim Abu NY, et al. Direct evidence of leukocyte adhesion in arterioles by angiotensin II. Blood. 2004;104:402–408
  16. Ruiz-Ortega M, Ruperez M, Lorenzo O, et al. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney International. Supplement. 2002;82:12–22
  17. Han Y, Runge MS, Brasier AR. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circulation Research. 1999;84:695–703
  18. Zacharieva S, Atanassova I, Nachev E, et al. Markers of vascular function in hypertension due to Cushing's syndrome. Hormone and Metabolic Research. 2005;37:36–39
  19. Zacharieva S, Atanassova I, Orbetzova M, et al. Vascular endothelial growth factor (VEGF), prostaglandin E2 (PGE2) and active renin in hypertension of adrenal origin. Journal of Endocrinological Investigation. 2004;27:742–746
  20. Touyz RM, Schiffrin EL. Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase sensitive pathways. Journal of Hypertension. 2001;19:1245–1254
  21. Napoli C, Ignarro LJ. Nitric oxide and atherosclerosis. Nitric Oxide. 2001;5:88–97
  22. Schiffrin EL. Role of endothelin-1 in hypertension and vascular disease. American Journal of Hypertension. 2001;14:S83–S89
  23. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. Journal of Hypertension. 1998;16:1081–1098
  24. Imai T, Hirata Y, Emori T, et al. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension. 1992;19:753–757
  25. Capricchione A, Winer N, Sowers RJ. Adrenocortical hypertension. Current Hypertension Reports. 2004;6:224–229
  26. Stewart MP. Cortisol as a mineralocorticoid in human disease. The Journal of Steroid Biochemistry and Molecular Biology. 1999;69:403–408
  27. Baid S, Nieman KL. Glucocorticoid excess and hypertension. Current Hypertension Reports. 2004;6:493–499
  28. Sacerdote A, Weiss K, Tran T, et al. Hypertension in patients with Cushing's disease: pathophysiology, diagnosis, and management. Current Hypertension Reports. 2005;7:212–218
  29. Danese RD, Aron DC. Cushing's syndrome and hypertension. Endocrinology and Metabolism Clinics of North America. 1994;23:299–324
  30. Kelly JJ, Mangos G, Williamson PM, et al. Cortisol and hypertension. Clinical and Experimental Pharmacology & Physiology. 1998;25(supplement):S51–S56
  31. Judith A, Whitworth JA, Mangos G, et al. Cushing, cortisol and cardiovascular disease. Hypertension. 2000;36:912–916
  32. Suzuki H, Handa M, Kondo K, et al. Role of renin-angiotensin system in glucocorticoid hypertension in rats. American Journal of Physiology. 1982;243:E48–E51
  33. Saruta T, Suzuki H, Handa M, et al. Multiple factors contributes to the pathogenesis of hypertension in Cushing's syndrome. The Journal of Clinical Endocrinology and Metabolism. 1986;62:275–279
  34. Handa M, Kondo K, Suzuki H, et al. Urinary prostaglandin E2 and kallikrein excretion in glucocorticoid hypertension in rats. Clinical Science. 1983;65:37–42
  35. Kelly JJ, Tam SH, Williamson PM, et al. The nitric oxide system and cortisol induced hypertension in humans. Clinical and Experimental Pharmacology & Physiology. 1988;25:945–946
  36. Pirpiris M, Yeung S, Dewar E, et al. Hydrocortisone-induced hypertension in man: the role of cardiac output. American Journal of Hypertension. 1993;6:287–294
  37. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. The Journal of Clinical Endocrinology and Metabolism. 2001;86:713–718
  38. Shipley JE, Schteingart DE, Tandon R, et al. Sleep architecture and sleep apnea in patients with Cushing's disease. Sleep. 1992;15:514–518
  39. Walker BR, Yau JL, Brett CP, et al. 11-β-hydroxysteroid dehydrogenase in vascular smooth muscle and heart. Implications for cardiovascular responses to glucocorticoids. Endocrinology. 1991;129:3305–3312
  40. Monder C, White PC. 11beta-hydroxysteroid dehydrogenase. Vitamins and Hormones. 1993;47:187–271
  41. Walker BR, Campbell JC, Williams BC, et al. Tissue-specific distribution of the NAD-dependent isoform of 11 betahydroxysteroid dehydrogenase. Endocrinology. 1992;131:970–972
  42. Smith RE, Maguire JA, Stein Oakley AN, et al. Localization of 11 beta-hydroxysteroid dehydrogenase type II in human epithelial tissues. The Journal of Clinical Endocrinology and Metabolism. 1996;81:3244–3248
  43. White PC. 11 beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess. The American Journal of Medical Sciences. 2001;322:308–315
  44. Ulick S, Wang JZ, Blumenfeld JD, et al. Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in ectopic adrenocorticotropin syndrome. The Journal of Clinical Endocrinology and Metabolism. 1992;74:963–967
  45. Van Uum SH, Lenders JW, Hermus AR. Cortisol, 11beta-hydroxysteroid dehydrogenases, and hypertension. Seminars in Vascular Medicine. 2004;4(2):121–128
  46. Torpy DJ, Mullen N, Ilias I, et al. Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases. Annals of the New York Academy of Sciences. 2002;970:134–144
  47. Klett C, Ganten D, Hellmann W, et al. Regulation of hepatic angiotensinogen synthesis and secretion by steroid hormones. Endocrinology. 1992;130:3660–3668
  48. Ritchie CM, Sheridan B, Fraser R, et al. Studies on the pathogenesis of hypertension in Cushing's disease and acromegaly. The Quarterly Journal of Medicine. 1990;76:855–867
  49. Sato A, Suzuki H, Murakami M, et al. Glucocorticoid increases angiotensin II type 1 receptor and its gene expression. Hypertension. 1994;23:25–30
  50. Kirilov G, Tomova A, Dakovska L, et al. Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing's syndrome. European Journal of Endocrinology. 2003;149:549–553
  51. Smith L, Smith JB. Regulation of sodium-calcium exchanger by glucocorticoids and growth factors in vascular smooth muscle. The Journal of Biological Chemistry. 1994;269:27527–27531
  52. Kelly JJ, Martin A, Whitwort JA. Role of erythropoietin in cortisol induced hypertension. Journal of Human Hypertension. 2000;14:195–198
  53. Langenfeld MR, Veelken R, Schobel HP, et al. Is endogenous erythropoietin a pathogenetic factor in the development of essential hypertension?. Nephrology, Dialysis, Transplantation. 1997;12:1155–1160
  54. Heidenreich S, Rahn K-H, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney International. 1991;39:259–265
  55. Scheuer DA, Bechtold AG. Glucocorticoids potentiate central actions of angiotensin to increase arterial pressure. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2001;280:R1719–R1726
  56. Sakaue M, Hoffman BB. Glucocorticoids induce transcription and expression of the α1β adrenergic receptor gene in DTT1 MF2-smooth muscle cells. Journal of Clinical Investigation. 1991;88:385–389
  57. Yasunari K, Kohno M, Murakava K, et al. Glucocorticoids and atrial natriuretic factor receptors on vascular smooth muscle. Hypertension. 1990;16:581–586
  58. Simmons WW, Ungureanue-Longrois D, Smith GK, et al. Glucocorticoids regulate inducible nitric oxide synthase by inhibiting tetrahydrobiopterin synthesis and L-arginine transport. The Journal of Biological Chemistry. 1996;271:23928–23937
  59. Cylwik D, Mogielnicki A, Buczko W. L-arginine and cardiovascular system. Pharmacological Reports. 2005;57:14–22
  60. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. The New England Journal of Medicine. 1993;27:2002–2012
  61. Moneva MH, Gomez-Sanchez CE. Pathophysiology of adrenal hypertension. Seminars in Nephrology. 2002;22:44–53
  62. Morris D, Grossman A. The medical management of Cushing's syndrome. Annals of the New York Academy of Sciences. 2002;970:119–133
  63. Nieman LK. Medical therapy of Cushing's disease. Pituitary. 2002;5:77–82
  64. Mampalam TJ, Tyrrell JB, Wilson CB. Transsphenoidal microsurgery in Cushing's disease. Annals of Internal Medicine. 1988;109:487–493
  65. Rees DA, Hanna FW, Davies JS, et al. Long term follow-up results of transsphenoidal surgery for Cushing's disease in a single centre using strict criteria for remission. Clinical Endocrinology (Oxford). 2002;56:541–551
  66. Hoybye C, Grenback E, Thoren M, et al. Transsphenoidal surgery in Cushing's disease: 10 years of experience in 34 consecutive cases. Journal of Neurosurgery. 2004;100:634–638
  67. Kobayashi T, Kida Y, Mori Y. Gamma knife radiosurgery in the treatment of Cushing disease: long-term results. Journal of Neurosurgery. 2002;97:422–428
  68. Mahmoud-Ahmed AS, Suh JH. Radiation therapy for Cushing's disease: a review. Pituitary. 2002;5:175–180
  69. Colao A, Pivonello R, Spiezia S, et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. The Journal of Clinical Endocrinology and Metabolism. 1999;84:2664–2672
  70. Vaughan ED. Diseases of the adrenal gland. The Medical Clinics of North America. 2004;88:443–466
  71. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003;42:1206–1252
  72. McMahon EG. Recent studies with eplerenone, a novel selective aldosterone antagonist. Current Opinion in Pharmacology. 2001;1:190–196
  73. Zacharieva S, Orbetzova M, Natchev E, et al. Losartan in Cushing's syndrome. Methods and Findings in Experimental and Clinical Pharmacology. 1998;20:163–168
  74. Zacharieva S, Torbova S, Orbetzova M, et al. Trandolapril in Cushing's disease: short-term trandolapril treatment in patients with Cushing's disease and essential hypertension. Methods and Findings in Experimental and Clinical Pharmacology. 1988;20:433–438
  75. Alevizaki M, Philippou G, Zapanti L, et al. Significant improvement of recurrent pituitary-dependent Cushing's syndrome after administration of a PPAR-gamma agonist. In: Program of the 86th Annual Meeting of the Endocrine Society, New Orleans. New Orleans, LA: Endocrine Society; 2004;p. 418
  76. Ambrosi B, Dall'Ast C, Cannavo S, et al. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. European Journal of Endocrinology. 2004;15:173–178
  77. El-Atat FA, Nicasio J, Clark LT, et al. An overview of the beneficial cardiovascular effects of thiazolidinediones. Therapy. 2005;2:113–119

PII: S1521-690X(06)00052-2

doi: 10.1016/j.beem.2006.07.006

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 3 , Pages 467-482 , September 2006

Article Tools

* Image Usage & Resolution